The new Lockdown Craze sweeping the globe. Welcome to our viewers on pbs in america and around the globe. Major trials of a new vaccine have shown its effective against some new variants of covid 19, helping to reduce fears that they might prove resistant. Novavax is an american jab but its being produced in the uk. Its also easier to roll out than some previous vaccines since it doesnt need to be kept at ultra low temperatures. The news came amid a deepening row between another vaccine maker, astrazeneca, and the European Union over shortages. Our medical editor fergus walsh reports. Once again, science has triumphed in the fight against coronavirus. The Us Firm Novavax has released results of its british trial showing the first proven efficacy against the new, more contagious uk variant. There were more than 15,000 volunteers on the trail throughout the uk. Over half the cases of covid recorded were the result of the new variant. The results showed the vaccine was 95 effective agains
, and i am Francine Lacqua, here in london. Merger, with moncler s. P. A. Buying stoneham. If you look at stocks, near record highs, a hope for a u. S. Stimulus deal, tampered concerns about coronavirus, and of course on the brexit front, the pound is rallying as u. K. Prime minister Boris Johnson is heading to brussels for a teteatete with the british european negotiator. Luxury on is a new the block, moncler has agreed to buy highend luxury brand stoneham in its first major acquisition. Turning down a takeover approach last year. Joining us, i am delighted, it remo ruffini, chief executive director of moncler. Thanks for joining us. Is this a new luxury conglomerate that you will create . I am, actually, you know, concentrated on the deal, because i am quite concentrated on the deal, having said that, never say never, because last friday, when we decided to close, and i prepared the press title was beyond station and beyond luxury. We need to find something to be as much unique as we
Astrazeneca is to resume vaccine trials. Virus numbers rise but travelers defy warnings to stay home. Imports of u. S. Goods closed slowed last month. David amidst all of that and a overnighthat markets we are getting futures coming online in about 60 minutes. Been a veryt has good past two weeks for global equities. The nikkei 225 flirting with 27,000. Kiwi dollar has been standing on the platform. They are not getting a lot of action. It has been about a weak dollar. About vaccineing reflation trade. Astrazeneca will run another global trial. Amid questions about the program and the level of protection. Initial test claims varying degrees of efficacy, sometimes as high as 90 . Our Deputy Managing Editor has the story. We have been asking a lot of the experts whether they can explain the gap between efficacy depending on the number of doses. No one has managed to come up with much of a thesis. Is that why there saying more trials are needed . Is that why they are saying more trials ar
Good morning, everyone. Welcome to bloomberg surveillance. I am Francine Lacqua here in london. A lot going on, because we have Christine Lagarde testifying in parliament. We will bring you anything that comes out of it. The markets focusing on infections rising around the world. They are focusing around the fact that we could see a stimulus. Lets get to the markets. I dont know if we have them. If we do, it could be great, and it would be a good time to look at them. Overall,ok at stocks they are falling along u. S. Futures, tougher restrictions, progress toward a vaccine. We have plenty more of course on that. Astrazeneca at rising amidst positive news on its coronavirus vaccine. We are hearing from Christine Lagarde. We had an exclusive conversation days ago. The focus is on the need for a stimulus. The focus is also on the need for markets to do a little bit more. She said basically the ecb delivered in the first wave. She is talking about the physical packages, on course for a fis
France threatens to get out of the rescue plan altogether. 11,000 jobs slashed, the german giant fights for survival. Welcome to the program. Looking at the futures, reflecting the way the european and u. S. Equity markets closed yesterday. Futures down in europe, mixed in the u. S. , reflecting what we saw yesterday were the u. S. Wobbled into the close at the end of the session. New york schools closing seems to be the factor. Breaking news, some commentary from astrazeneca in connection phasehase two, not the three news we have been waiting for. That is expected to come within weeks. This is more detail on the phase two data. They are confirming the vaccines immune response in older adults, that is crucial considering who is most vulnerable to the virus. The lancet is publishing the findings. A lot of stuff we have heard already from phase three trials more advanced than this from other drug companies. It has not been peerreviewed or in journals. We are getting the phase two study,